Nonetheless, current data from our investigation suggest that point mutation W402A (human W403A) in Parkin by itself is not sufficient to provide cardiac protection or promote mitophagy in vivo under the challenge by endotoxemia. The gene discussed is PRKN; the disease is serum lipopolysaccharide activity.